Strides Pharma Science : Intimation of Board Meeting scheduled on Sept 25, 2023
September 21, 2023 at 05:55 am
Share
September 20, 2023
BSE Limited
The National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers,
Exchange Plaza, Bandra-Kurla Complex
Dalal Street, Mumbai - 400 001
Bandra (E) Mumbai - 400 051
Scrip code: 532531
Scrip code: STAR
Dear Madam/ Sir,
Sub: Intimation of Board Meeting and Investors Call
We refer to Company's announcement of August 2, 2023 as part of Q1 FY24 Earnings Presentation about our intent to combine CDMO interests of the group to become one of India's top specialty pharmaceuticals CDMOs.
We now wish to inform you that a board meeting of the Company is scheduled to be held on Monday, September 25, 2023 to consider the above proposal.
The Company will also host a call on Monday, September 25, 2023 at 17:00 hrs IST to interact with the investors in connection with the above proposal.
Strides Pharma Science Ltd. published this content on 21 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2023 04:54:06 UTC.
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche and pharmaceutical products. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.